Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
We recently reported on a potent synthetic agent, 135H11, that selectively targets the receptor tyrosine kinase, EphA2. While 135H11 possesses a relatively high binding affinity for the ligand-binding domain of EphA2 (Kd~130 nM), receptor activation in the cell required the synthesis of dimeric vers...
| Published in: | Molecules |
|---|---|
| Main Authors: | Parima Udompholkul, Carlo Baggio, Luca Gambini, Yu Sun, Ming Zhao, Robert M. Hoffman, Maurizio Pellecchia |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/12/3687 |
Similar Items
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
by: Ahmed F. Salem, et al.
Published: (2020-05-01)
by: Ahmed F. Salem, et al.
Published: (2020-05-01)
Serum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer
by: Shunsuke Sakuraba, et al.
Published: (2024-11-01)
by: Shunsuke Sakuraba, et al.
Published: (2024-11-01)
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
by: Hatano Manabu, et al.
Published: (2004-11-01)
by: Hatano Manabu, et al.
Published: (2004-11-01)
The EphA2 Receptor Regulates Invasiveness and Drug Sensitivity in Canine and Human Osteosarcoma Cells
by: Evelyn D. Harris, et al.
Published: (2024-07-01)
by: Evelyn D. Harris, et al.
Published: (2024-07-01)
EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer
by: Miaomiao Zhang, et al.
Published: (2024-12-01)
by: Miaomiao Zhang, et al.
Published: (2024-12-01)
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
by: Walid Kamoun, et al.
Published: (2020-10-01)
by: Walid Kamoun, et al.
Published: (2020-10-01)
Ephrin A1 ligand‐based CAR‐T cells for immunotherapy of EphA2‐positive cancer
by: Nan Liu, et al.
Published: (2025-03-01)
by: Nan Liu, et al.
Published: (2025-03-01)
The Role of Biomarkers in the Early Diagnosis of Gastric Cancer: A Study on CCR5, CCL5, PDGF, and EphA7
by: Süleyman Bademler, et al.
Published: (2024-09-01)
by: Süleyman Bademler, et al.
Published: (2024-09-01)
A biocompatible nanoformulation of curcumin analogue and curd exosomes targeting EphA2 signalling cascade in head and neck cancer
by: Kaumudi Pande, et al.
Published: (2024-09-01)
by: Kaumudi Pande, et al.
Published: (2024-09-01)
CBX7 regulates metastasis of basal-like breast cancer through Twist1/EphA2 pathway
by: Tao Dai, et al.
Published: (2022-10-01)
by: Tao Dai, et al.
Published: (2022-10-01)
The role of EphA2 in ADAM17- and ionizing radiation-enhanced lung cancer cell migration
by: Verena Waller, et al.
Published: (2023-03-01)
by: Verena Waller, et al.
Published: (2023-03-01)
Development of an In-House EphA2 ELISA for Human Serum and Measurement of Circulating Levels of EphA2 in Hypertensive Patients with Renal Dysfunction
by: Maki Murakoshi, et al.
Published: (2022-12-01)
by: Maki Murakoshi, et al.
Published: (2022-12-01)
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells
by: Julien Cicero, et al.
Published: (2023-12-01)
by: Julien Cicero, et al.
Published: (2023-12-01)
Targeting the EphA2 pathway: could it be the way for bone sarcomas?
by: Giorgia Giordano, et al.
Published: (2024-09-01)
by: Giorgia Giordano, et al.
Published: (2024-09-01)
Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications
by: Hiroyuki Satofuka, et al.
Published: (2025-06-01)
by: Hiroyuki Satofuka, et al.
Published: (2025-06-01)
Unveiling the therapeutic promise of EphA2 in glioblastoma: a comprehensive review
by: Caohang Qiu, et al.
Published: (2024-09-01)
by: Caohang Qiu, et al.
Published: (2024-09-01)
EphA2 is a biomarker of hMSCs derived from human placenta and umbilical cord
by: Shih-Pei Shen, et al.
Published: (2015-12-01)
by: Shih-Pei Shen, et al.
Published: (2015-12-01)
Plasma EphA2 level is a superior biomarker to Del-1 for sepsis diagnosis and prognosis
by: Eun Hye Lee, et al.
Published: (2025-01-01)
by: Eun Hye Lee, et al.
Published: (2025-01-01)
EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway [Retraction]
by: Zhang R, et al.
Published: (2025-07-01)
by: Zhang R, et al.
Published: (2025-07-01)
Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer
by: Lidia Moyano‐Galceran, et al.
Published: (2020-03-01)
by: Lidia Moyano‐Galceran, et al.
Published: (2020-03-01)
EphrinA2 promotes glioma cell migration and invasion through EphA2 and FAK
by: Nozomi Hirai, et al.
Published: (2025-05-01)
by: Nozomi Hirai, et al.
Published: (2025-05-01)
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence
by: Claudio Festuccia, et al.
Published: (2023-10-01)
by: Claudio Festuccia, et al.
Published: (2023-10-01)
Engineering a nano delivery system targets EphA2 for treating colorectal cancer oxaliplatin resistant
by: Zhengshuo Li, et al.
Published: (2025-12-01)
by: Zhengshuo Li, et al.
Published: (2025-12-01)
Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment
by: Jin Gu Cho, et al.
Published: (2025-10-01)
by: Jin Gu Cho, et al.
Published: (2025-10-01)
Dihydroartemisinin inhibits EphA2/PI3K/Akt pathway-mediated malignant behaviors and vasculogenic mimicry in glioma stem cells
by: Huangde Fu, et al.
Published: (2025-02-01)
by: Huangde Fu, et al.
Published: (2025-02-01)
Targeting EphA2 suppresses the proliferation, migration and invasion of endometriosis via the AMPK signaling pathway
by: Chaoyi Yang, et al.
Published: (2025-06-01)
by: Chaoyi Yang, et al.
Published: (2025-06-01)
EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy
by: Zhenggang Wang, et al.
Published: (2024-03-01)
by: Zhenggang Wang, et al.
Published: (2024-03-01)
The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis
by: Jenni Lahtela, et al.
Published: (2015-04-01)
by: Jenni Lahtela, et al.
Published: (2015-04-01)
Sam-Sam Association Between EphA2 and SASH1: In Silico Studies of Cancer-Linked Mutations
by: Marian Vincenzi, et al.
Published: (2025-02-01)
by: Marian Vincenzi, et al.
Published: (2025-02-01)
Development and Evaluation of an Anti-Biotin Interference Method in Biotin-Streptavidin Immunoassays
by: Dong Liu, et al.
Published: (2022-07-01)
by: Dong Liu, et al.
Published: (2022-07-01)
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
by: Giorgia Giordano, et al.
Published: (2021-10-01)
by: Giorgia Giordano, et al.
Published: (2021-10-01)
COE targets EphA2 to inhibit vasculogenic mimicry formation induced by hypoxia in hepatocellular carcinoma
by: Jue Chen, et al.
Published: (2024-07-01)
by: Jue Chen, et al.
Published: (2024-07-01)
EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/maturation and promote cell adhesion and protrusion formation in HL60 monocytes
by: Midori Mukai, et al.
Published: (2017-08-01)
by: Midori Mukai, et al.
Published: (2017-08-01)
Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry
by: Hiroyuki Satofuka, et al.
Published: (2025-09-01)
by: Hiroyuki Satofuka, et al.
Published: (2025-09-01)
A novel pH-dependent membrane peptide that binds to EphA2 and inhibits cell migration
by: Daiane S Alves, et al.
Published: (2018-09-01)
by: Daiane S Alves, et al.
Published: (2018-09-01)
Serum levels of EphA2 are elevated in knee osteoarthritis and associated with disease severity
by: Maping Xiao, et al.
Published: (2025-10-01)
by: Maping Xiao, et al.
Published: (2025-10-01)
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
by: Malgorzata Gajdzis, et al.
Published: (2020-09-01)
by: Malgorzata Gajdzis, et al.
Published: (2020-09-01)
Effect of EphA7 Silencing on Proliferation, Invasion and Apoptosis in Human Laryngeal Cancer Cell Lines Hep-2 and AMC-HN-8
by: Cheng Xiang, et al.
Published: (2015-05-01)
by: Cheng Xiang, et al.
Published: (2015-05-01)
Neuronal guanine nucleotide exchange factor promotes the axonal growth and cancer cell proliferation via Ephrin-A3/EphA2 axis in lung adenocarcinoma
by: Jie Mi, et al.
Published: (2025-02-01)
by: Jie Mi, et al.
Published: (2025-02-01)
Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR
by: Pui Yeng Lam, et al.
Published: (2025-01-01)
by: Pui Yeng Lam, et al.
Published: (2025-01-01)
Similar Items
-
Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
by: Ahmed F. Salem, et al.
Published: (2020-05-01) -
Serum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer
by: Shunsuke Sakuraba, et al.
Published: (2024-11-01) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
by: Hatano Manabu, et al.
Published: (2004-11-01) -
The EphA2 Receptor Regulates Invasiveness and Drug Sensitivity in Canine and Human Osteosarcoma Cells
by: Evelyn D. Harris, et al.
Published: (2024-07-01) -
EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer
by: Miaomiao Zhang, et al.
Published: (2024-12-01)
